Home › Endometrial Cancer › Massachusetts
Endometrial Cancer clinical trials in Massachusetts
54 studies for Endometrial Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
RecruitingPhase 1
Ages 18 and older · Women · Updated Nov 13, 2026 · NCT06964009A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 16 and older · All sexes · Updated Nov 12, 2026 · NCT07197554A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- and 1 more
RecruitingPhase 2
All ages · All sexes · Updated Nov 12, 2026 · NCT05564377Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Massachusetts General Hospital Cancer Center, Boston
- Baystate Medical Center, Springfield
- UMass Memorial Medical Centre, Worcester
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 12, 2026 · NCT05640999A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Tufts Medical Center ( Site 6052), Boston
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 10, 2026 · NCT06952504A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06515613Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Dana-Farber Cancer Institute, Boston
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 6, 2026 · NCT07198074A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Nov 5, 2026 · NCT06586957Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07059884A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06760819Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- UMass Memorial Medical Ctr, Worcester
RecruitingPhase 3
Ages 18 and older · Women · Updated Nov 3, 2026 · NCT07166094A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06774963A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
- Massachusetts General Brigham, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2026 · NCT07807345A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07383506A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT04657068Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06239194ALPINE: Maintenance Letrozole/Abemaciclib
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06366347Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05123482DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Boston
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 13, 2026 · NCT06989112Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06993844FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 7, 2026 · NCT05919264Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05797168A Study of PHST001 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06840886The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 25, 2026 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT07755436Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · Women · Updated Aug 31, 2026 · NCT04839614A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT07227168Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.